THE VALUE OF VOLUMETRIC MEASUREMENT OF MALIGNANT PLEURAL MESOTHELIOMA (MPM) TO ASSESS THE THERAPY RESPONSE

被引：0
|
作者：
Tutic, M.
Frauenfelder, T. [1 ]
Schramm, A. [2 ]
Goetti, R. P. [3 ]
Weder, W.
Marincek, B. [5 ]
Opitz, I. [4 ]
机构：
[1] Inst Diagnost Radiol, Zurich, Switzerland
[2] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[3] Div Radiol, Zurich, Switzerland
[4] Univ Zurich Hosp, Dept Thorac Surg, CH-8091 Zurich, Switzerland
[5] Inst Radiol, Zurich, Switzerland
来源：
LUNG CANCER | 2009年 / 64卷
关键词：
D O I：
10.1016/S0169-5002(09)70273-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [31] Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)
    Nowak, A. K.
    Millward, M. J.
    Francis, R.
    van der Schaaf, A.
    Musk, A. W.
    Byrne, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Intensity modulated hemithoracic radiation therapy for malignant pleural mesothelioma (MPM) after pleureciomy/decortication
    Rosenzweig, K. E.
    Krug, L. M.
    Flores, R. M.
    Yorke, E. D.
    Mageras, G. M.
    Nehineh, S.
    Erdi, Y.
    Stechel, E.
    Rusch, V. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S494 - S495
  • [33] Prognostic factors in malignant pleural mesothelioma (MPM): A mono-institutional evaluation of Bologna Malignant Pleural Mesothelioma Group.
    Adua, Daniela
    Sperandi, Francesca
    Castellucci, Paolo
    Melotti, Barbara
    Giaquinta, Stefania
    Fanti, Stefano
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Real-world use of systemic therapy in elderly patients with malignant pleural mesothelioma (MPM)
    Cedres, S.
    Assaf, J. D.
    Iranzo, P.
    Callejo, A.
    Pardo, N.
    Navarro, A.
    Martinez-Marti, A.
    Rodriguez, G.
    Monton, V.
    Gonzalo, J.
    Miquel, J. M.
    Pedrola, A.
    Dienstmann, R.
    Felip, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [35] Real World use of Cisplatin and Carboplatin Based Therapy in Patients with Malignant Pleural Mesothelioma (MPM)
    Cedres, S.
    Assaf, J. D.
    Iranzo, P.
    Callejo, A.
    Pardo, N.
    Navarro, A.
    Martinez-Marti, A.
    Valdivia, A.
    Filipi-Arriaga, F.
    Monton, V.
    Gonzalo, J.
    Pedrola, A.
    Recasens, S.
    Madrenas, R.
    Feliu, B.
    Roman, B.
    Dienstmann, R.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S379 - S380
  • [36] Feasibility Study of Volumetric Modulated Arc Therapy for Malignant Pleural Mesothelioma Tumor
    Cozzi, L.
    Bignardi, M.
    Fogliata, A.
    Lattuada, P.
    Mancosu, P.
    Navarria, P.
    Urso, G.
    Vigorito, S.
    Seorsetti, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S715 - S715
  • [37] A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma
    Li Runxiao
    Cao Yankun
    Wang Lan
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2016, 17 (02): : 139 - 144
  • [38] The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
    Yuen, Man Lee
    Zhuang, Ling
    Rath, Emma M.
    Yu, Takun
    Johnson, Ben
    Sarun, Kadir Harun
    Wang, Yiwei
    Kao, Steven
    Linton, Anthony
    Clarke, Candice Julie
    McCaughan, Brian C.
    Takahashi, Ken
    Lee, Kenneth
    Cheng, Yuen Yee
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [39] Prognostic Value of FDG-PET/CT in Therapy Response Evaluation of Malignant Pleural Mesothelioma
    Veit-Haibach, P.
    Schaefer, N.
    Soyka, J.
    Strobel, K.
    Hany, T.
    Steinert, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S138 - S139
  • [40] SOLUBLE MESOTHELIN RELATED PROTEIN (SMRP) IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Azim, H. A., Jr.
    Gaafar, R.
    Abdelsalam, I.
    Khorshid, O.
    Elguindi, S.
    Elattar, I.
    Ashmawy, A.
    LUNG CANCER, 2009, 64 : S66 - S66
12345